基于人乳头瘤病毒主要衣壳蛋白L1的疫苗研究进展  

Advance in human papillomavirus major capsid protein L1-based vaccines

作　　者：华春婷 孙思源 程浩[1] 韩睿[1] Hua Chunting;Sun Siyuan;Cheng Hao;Han Rui(Department of Dermatology,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou 310016,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院皮肤科,杭州310016

出　　处：《中华微生物学和免疫学杂志》2019年第10期788-793,共6页Chinese Journal of Microbiology and Immunology

基　　金：浙江省医药卫生科技计划(2018KY459,2018PY024);浙江省中医药科技计划(2018ZQ037)。

摘　　要：人乳头瘤病毒(human papillomavirus,HPV)主要衣壳蛋白由晚期基因(late gene 1,L1)表达,可以自发组装成病毒样颗粒(virus like particle,VLP)且具有良好免疫原性而被用于HPV免疫致病机制及HPV疫苗的研究.然而,现有以L1为基础的疫苗存在一定局限性,如L1蛋白表达量低、纯化过程复杂使得疫苗产量较低;L1蛋白中和抗体为HPV型特异而不同型HPV的交叉保护率很低;此外,对已有的HPV感染清除作用不确定且不具有治疗HPV相关疾病的作用.本文将对HPV L1的结构、免疫原性与在免疫应答中的作用、包括L1为基础的HPV疫苗的发展现状与最新进展进行综述.L1 is the major capsid protein of human papillomavirus(HPV)encoded by late gene 1.Based on the fact that L1 can self-assemble into virus like particle(VLP)with good immunogenicity,it has aroused wide concern in studying the pathogenesis of and vaccines against HPV.Nevertheless,there are a few limitations of present L1-based HPV vaccines.For instance,low expression of the protein and the com-plexity of purification result in the relatively low yield of vaccines.Type-specific antibody induced by L1 also results in the unsatisfactory cross-protection rate.Furthermore,there is no reported therapeutic effect against HPV-related diseases because of its undefined role in virus eliminating.This review focused on the struc-ture,immunogenicity and role in immune response of L1 and the development of and latest progress in HPV vaccines.

关 键 词：人乳头瘤病毒 主要衣壳蛋白L1 病毒样颗粒 HPV疫苗 

分 类 号：R73[医药卫生—肿瘤]